Routes of
administration Oral Legal status US: ℞-only Molar mass 765.88 g/mol | ATC code J05AX66 (WHO) Bioavailability was not evaluated | |
 | ||
Trade names Viekira Pak (in combination with ombitasvir, ritonavir and dasabuvir), Technivie/Viekirax (in combination with ombitasvir and ritonavir) Pregnancy
category US: B (No risk in non-human studies) | ||
How to pronounce ombitasvir paritaprevir ritonavir dasabuvir viekira pak memorizing pharmacology
Paritaprevir (previously known as ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.p. 248
Contents
- How to pronounce ombitasvir paritaprevir ritonavir dasabuvir viekira pak memorizing pharmacology
- Paritaprevir ritonavir ombitasvir dasabuvir for hcv gt1 video abstract 80226
- References
Paritaprevir is a component of Viekira Pak and Technivie.
Paritaprevir ritonavir ombitasvir dasabuvir for hcv gt1 video abstract 80226
References
Paritaprevir Wikipedia(Text) CC BY-SA